Comparative Pharmacology
Head-to-head clinical analysis: NAPROXEN SODIUM versus PROFENAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPROXEN SODIUM versus PROFENAL.
NAPROXEN SODIUM vs PROFENAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
220-550 mg orally twice daily; maximum 1375 mg/day.
600 mg orally every 6 to 8 hours as needed for pain; or 1000 mg orally every 6 to 8 hours for antipyresis; maximum single dose 1000 mg, maximum daily dose 4000 mg.
None Documented
None Documented
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
6-8 hours (terminal); requires dosing every 6-8 hours to maintain therapeutic levels
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Primarily renal (approximately 70% as metabolites, <5% unchanged), biliary/fecal (30%)
Category D/X
Category C
NSAID
NSAID